Topics

BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib

11:54 EST 15 Jan 2019 | Investing News Network

BeiGene (NASDAQ:BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, for the treatment of adult patients with mantle … Continued

The post BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib appeared first on Investing News Network.

Original Article: BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib

NEXT ARTICLE

More From BioPortfolio on "BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib"

Quick Search

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...